^
Association details:
| Biomarker: | EGFR G719A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Excerpt:
...Exon 19 deletion; G719S, G719A, G719C mutations (Exon 19);or L861Q (laboratory report required at enrollment)....
Source:
Title:
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Excerpt:
Clinical outcomes for rare mutations or rare combinations of mutations.
DOI:
10.1158/1078-0432.CCR-09-0888
Source:
Title:
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Excerpt:
...recent studies revealed that these rare genotypes could be targetable if appropriate TKI are selected. For example, G719X (X denotes A, S, C and so on), Del18, E709K, insertions in exon 19 (Ins19), S768I or L861Q showed moderate sensitivities to gefitinib or erlotinb with ORR of 30%–50%
DOI:
10.1111/cas.12996
Source:
Title:
Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations: A Prospective Study
Excerpt:
In conclusion, this prospective study demonstrated a high correlation (72.4%) in the radiological response between early (Day 14) and regular evaluation time (Day 56), and a very high percentage (21/29, 72.4%) of early radiological response to EGFR‑TKIs in NSCLC patients with EGFR mutations and PR, which would advocate early radiological examination for EGFR‑TKI therapy in NSCLC patients.
DOI:
10.4103/2319-4170.138320
